This website uses cookies. By using the site you are agreeing to our Privacy Policy.

Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.

Main menu starts here.
Skip the main menu to current location in your website.

Current location in your website.
Skip to main contents.

What's New


The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.

Changes in Major Shareholder
September 9, 2002
Toyama Chemical Co., Ltd. (hereinafter referred to as "Toyama") has decided upon allocation of new stock to a third party at the board meeting held on September 9, 2002. Accordingly, the major shareholder in Toyama has been changed as follows:
1. Reason for changes in major shareholders
Toyama's allocation of new stock to a third party has been accepted by Taisho Pharmaceutical Co., Ltd. (hereinafter referred to as "Taisho").
2. Major shareholder
Name Taisho Pharmaceutical Co., Ltd.
Head office 24-1, Takada 3-chome, Toshima-ku, Tokyo, Japan
Representative Akira Uehara, President
Business description Manufacturing and sales of pharmaceutical products
3. Number of shares held by Taisho (number of votes) and ratio of shareholding to number of all voting shares
  Number of shares held
(number of votes)
Ratio of shareholding* Ranking
Before change
(Sept. 25, 2002)
0 (0) - -
After change 43,000,000(43,000) 22.3% 1
  * Number of shares calculated subtracting the number of nonvoting shares from the total number of outstanding shares: 4,079,182
Total number of outstanding shares as of March 31, 2002: 153,766,182
4. Expected date of change: September 26, 2002
5. Perspective after alliance with Taisho
Toyama aims to ensure remarkable growth as a research-based company by establishing a strong partnership with Taisho while maximizing investment efficiency in the R&D area through capital alliance with Taisho.
Footer starts here.

Pages ends here.
Move to top of the page.